Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.

Aethlon Medical, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SAN DIEGO , DEC. 5, 2025 /PRNEWSWIRE/ -- AETHLON MEDICAL, INC. ("AETHLON" OR THE "COMPANY") (NASDAQ: AEMD), A MEDICAL THERAPEUTIC COMPANY FOCUSED ON DEVELOPING PRODUCTS TO TREAT CANCER AND LIFE-THREATENING INFECTIOUS DISEASES, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A SECURITIES PURCHASE AGREEMENT WITH A SINGLE INSTITUTIONAL INVESTOR TO PURCHASE 595,897 SHARES OF COMMON STOCK (OR PRE-FUNDED WARRANTS IN-LIEU THEREOF), TOGETHER WITH WARRANTS TO PURCHASE UP TO AN AGGREGATE 1,042,820SHARES OF COMMON STOCK, IN A PRIVATE PLACEMENT PRICED AT-THE-MARKET UNDER NASDAQ RULES. THE COMBINED EFFECTIVE OFFERING PRICE FOR EACH SHARE OF COMMON STOCK (OR PRE-FUNDED WARRANT IN-LIEU THEREOF) AND ACCOMPANYING WARRANTS IS $4.03.

AETHLON MEDICAL ANNOUNCES PRICING OF A PRIVATE PLACEMENT AND WARRANT INDUCEMENT, PRICED AT-THE-MARKET FOR AGGREGATE GROSS PROCEEDS OF $3.3 MILLION

RESULTS SUPPORT THE FURTHER INVESTIGATION OF THE HEMOPURIFIER IN LONG COVID SAN DIEGO , DEC. 2, 2025 /PRNEWSWIRE/ -- AETHLON MEDICAL, INC. (NASDAQ: AEMD), A MEDICAL THERAPEUTIC COMPANY FOCUSED ON DEVELOPING PRODUCTS TO TREAT CANCER AND LIFE-THREATENING INFECTIOUS DISEASES, ANNOUNCED TODAY THE 20 NOVEMBER 2025 PUBLICATION OF A PRE-CLINICAL STUDY ENTITLED "INCREASED MANNOSYLATION OF EXTRACELLULAR VESICLES IN LONG COVID PLASMA PROVIDES A POTENTIAL THERAPEUTIC TARGET FOR GALANTHUS NIVALIS AGGLUTININ (GNA) AFFINITY RESIN" IN THE PRE-PRINT ONLINE ARCHIVE BIORXIV: HTTPS://WWW.BIORXIV.ORG/CGI/CONTENT/SHORT/2025.11.21.689519V1. THIS PAPER HAS SIMULTANEOUSLY BEEN SUBMITTED FOR CONSIDERATION TO A PEER-REVIEWED JOURNAL.

AETHLON MEDICAL ANNOUNCES PUBLICATION OF PRECLINICAL DATA SHOWING THAT THE GNA AFFINITY RESIN IN THE HEMOPURIFIER BINDS TO EXTRACELLULAR VESICLES IN LONG COVID PATIENT SAMPLES AND DECREASES INFLAMMATORY MICRORNAS

CLINICAL AND RESEARCH PROGRESS CONTINUES ALONGSIDE SUBSTANTIAL COST REDUCTIONS. CONFERENCE CALL TODAY AT 4:30 P.M.

AETHLON MEDICAL ANNOUNCES FISCAL Q2 2025 FINANCIAL RESULTS AND CORPORATE UPDATE

SAN DIEGO , NOV. 7, 2025 /PRNEWSWIRE/ -- AETHLON MEDICAL, INC. (NASDAQ: AEMD), A MEDICAL THERAPEUTIC COMPANY FOCUSED ON DEVELOPING PRODUCTS TO TREAT CANCER AND LIFE THREATENING INFECTIOUS DISEASES, TODAY ANNOUNCED THAT IT WILL ISSUE FINANCIAL RESULTS FOR ITS FISCAL SECOND QUARTER ENDED SEPTEMBER 30, 2025, AT 4:15 P.M. ET ON WEDNESDAY, NOVEMBER 12, 2025.

AETHLON MEDICAL TO RELEASE FISCAL SECOND QUARTER FINANCIAL RESULTS AND HOST CONFERENCE CALL ON NOVEMBER 12, 2025

SAN DIEGO , OCT. 7, 2025 /PRNEWSWIRE/ -- AETHLON MEDICAL, INC. ("AETHLON" OR THE "COMPANY") (NASDAQ: AEMD) TODAY PROVIDED OBSERVATIONS ON THE PRELIMINARY CHANGES IN EXTRACELLULAR VESICLE (EV), MICRORNA AND LYMPHOCYTE COUNTS IN THE FIRST PATIENT COHORT IN ITS ONGOING ONCOLOGY CLINICAL TRIAL IN AUSTRALIA. THE STUDY IS A SAFETY, FEASIBILITY, AND DOSE-FINDING TRIAL EVALUATING THE COMPANY'S HEMOPURIFIER (HP) IN PATIENTS WITH CANCER NOT RESPONDING TO ANTI-PD-1 THERAPY.

AETHLON MEDICAL'S HEMOPURIFIER SHOWS CHANGES IN EXTRACELLULAR VESICLES, EXTRACELLULAR MICRORNAS, AND T CELL NUMBERS IN AUSTRALIAN ONCOLOGY CLINICAL TRIAL

SAN DIEGO , SEPT. 4, 2025 /PRNEWSWIRE/ -- AETHLON MEDICAL, INC. ("AETHLON" OR THE "COMPANY") (NASDAQ: AEMD), A MEDICAL THERAPEUTIC COMPANY FOCUSED ON DEVELOPING PRODUCTS TO TREAT CANCER AND LIFE-THREATENING INFECTIOUS DISEASES, TODAY ANNOUNCED THE PRICING OF A PUBLIC OFFERING OF AN AGGREGATE OF 5,000,000 SHARES OF ITS COMMON STOCK (OR PRE-FUNDED WARRANTS IN LIEU THEREOF) AND WARRANTS TO PURCHASE UP TO 5,000,000 SHARES OF COMMON STOCK AT A COMBINED PUBLIC OFFERING PRICE OF $0.90 PER SHARE (OR PRE-FUNDED WARRANT) AND ACCOMPANYING WARRANT.

AETHLON MEDICAL ANNOUNCES PRICING OF $4.5 MILLION PUBLIC OFFERING

AUSTRALIAN CANCER TRIAL ADVANCES WITH FIRST COHORT COMPLETE, AMENDED PROTOCOL, AND PROMISING PRECLINICAL DATA PUBLISHED; OPERATING EXPENSES CUT BY 32% CONFERENCE CALL TO BE HELD TODAY AT 4:30 P.M. ET SAN DIEGO , AUG. 13, 2025 /PRNEWSWIRE/ -- AETHLON MEDICAL, INC. (THE COMPANY OR AETHLON) (NASDAQ: AEMD), A MEDICAL THERAPEUTIC COMPANY FOCUSED ON DEVELOPING PRODUCTS TO TREAT CANCER AND LIFE-THREATENING INFECTIOUS DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR ITS FISCAL FIRST QUARTER ENDED JUNE 30, 2025, AND PROVIDED AN UPDATE ON RECENT DEVELOPMENTS.

AETHLON MEDICAL ANNOUNCES FINANCIAL RESULTS FOR THE FISCAL FIRST QUARTER ENDED JUNE 30, 2025, AND PROVIDES CORPORATE UPDATE

SAN DIEGO , AUG. 5, 2025 /PRNEWSWIRE/ -- AETHLON MEDICAL, INC. (NASDAQ: AEMD), A MEDICAL THERAPEUTIC COMPANY FOCUSED ON DEVELOPING PRODUCTS TO TREAT CANCER AND LIFE THREATENING INFECTIOUS DISEASES, TODAY ANNOUNCED THAT IT WILL ISSUE FINANCIAL RESULTS FOR ITS FISCAL FIRST QUARTER ENDED JUNE 30, 2025, AT 4:15 P.M. ET ON WEDNESDAY, AUGUST 13, 2025.

AETHLON MEDICAL TO RELEASE FISCAL FIRST QUARTER FINANCIAL RESULTS AND HOST CONFERENCE CALL ON AUGUST 13, 2025

SAN DIEGO , JULY 15, 2025 /PRNEWSWIRE/ -- AETHLON MEDICAL, INC. (NASDAQ: AEMD), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING THE INVESTIGATIONAL AETHLON HEMOPURIFIER, AN EXTRACORPOREAL DEVICE FOR ONCOLOGY AND OTHER INDICATIONS, TODAY ANNOUNCED THAT THE INDEPENDENT DATA SAFETY MONITORING BOARD (DSMB) OVERSEEING ITS ONGOING CLINICAL TRIAL AEMD-2022-06 HAS COMPLETED ITS SCHEDULED SAFETY REVIEW AND RECOMMENDED ADVANCING TO THE NEXT PATIENT COHORT WITHOUT MODIFICATION. THE TRIAL, TITLED "SAFETY, FEASIBILITY, AND DOSE-FINDING STUDY OF AETHLON HEMOPURIFIER IN PATIENTS WITH SOLID TUMORS WHO HAVE STABLE OR PROGRESSIVE DISEASE WHILE ON A TREATMENT THAT INCLUDES PEMBROLIZUMAB OR NIVOLUMAB", IS BEING CONDUCTED TO ASSESS THE HEMOPURIFIER'S SAFETY, FEASIBILITY, AND OPTIMAL DOSING.

AETHLON MEDICAL, INC. ANNOUNCES POSITIVE DATA SAFETY MONITORING BOARD REVIEW AND RECOMMENDATION TO ADVANCE TO NEXT CLINICAL TRIAL COHORT

THREE PATIENTS TREATED IN HEMOPURIFIER CANCER TRIAL; INDIAN REGULATORY APPROVAL ACHIEVED; OPERATING EXPENSES REDUCED; R&D ADVANCES SUPPORT EXPANDED INDICATIONS INCLUDING LONG COVID CONFERENCE CALL TO BE HELD TODAY AT 4:30 P.M. ET SAN DIEGO , JUNE 26, 2025 /PRNEWSWIRE/ -- AETHLON MEDICAL, INC. (THE COMPANY OR AETHLON) (NASDAQ: AEMD), A MEDICAL THERAPEUTIC COMPANY FOCUSED ON DEVELOPING PRODUCTS TO TREAT CANCER AND LIFE-THREATENING INFECTIOUS DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR ITS FISCAL FOURTH QUARTER ENDED MARCH 31, 2025, AND PROVIDED AN UPDATE ON RECENT DEVELOPMENTS.

Aethlon Medical, Inc.

AEMD

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Aethlon Medical, Inc.

AEMD.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

AEMD